A review of patient-reported outcome labels in the United States: 2006 to 2010

Value in Health

Volumn 15, Issue 3, 2012, Pages 437-442

  Gnanasakthy, Ari ^a   Mordin, Margaret ^b   Clark, Marci ^b   Demuro, Carla ^b   Fehnel, Sheri ^b   Copley Merriman, Catherine ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

drug labeling; patient reported outcomes

Indexed keywords

ANESTHETIC AGENT; ANTIALLERGIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DENOSUMAB; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; HORMONE; NEUROLEPTIC AGENT;

DRUG EFFICACY; DRUG LABELING; DRUG PACKAGING; FOOD AND DRUG ADMINISTRATION; HUMAN; LICENCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 84861163178     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.032     Document Type: Article

References (18)

1. J. Avorn, W. Shrank Highlights and a hidden hazard: the FDA's new labeling regulations N Engl J Med 354 2006 2409 2411 (Pubitemid 43855042)
2. C. Acquadro, R. Berzon, D. Dubois Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001 Value Health 6 2003 522 531 (Pubitemid 37187713)
3. L.B. Burke, D.L. Kennedy, P.H. Miskala The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval Clin Pharmacol Ther 84 2008 281 283
4. S.N. Shah, A.M. Sesti, K. Copley-Merriman Quality of life terminology included in package inserts for US approved medications Qual Life Res 12 2003 1107 1117 (Pubitemid 37386638)
5. S. Wood-Dauphinee Assessing quality of life in clinical research: from where have we come and where are we going? J Clin Epidemiol 52 1999 355 363 (Pubitemid 29305307)
6. US Department of Health and Human Services Draft guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims http://www.fda.gov/ohrms/dockets/98fr/06d-0044-gdl0001.pdf February 2006 [Accessed January 14, 2011]
7. US Department of Health and Human Services Guidance for industry Patient-reported outcome measures: use in medical product development to support labeling claims http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf December 2009 [Accessed January 14, 2011]
8. J.A. Sloan, M.Y. Halyard, M.H. Frost The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes Value Health 10 Suppl. 2 2007 S59 S63
9. J. Speight, S.M. Barendse FDA guidance on patient reported outcomes BMJ 340 2010 c2921
10. R.J. Willke, L.B. Burke, P. Erickson Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels Control Clin Trials 25 2004 535 552 (Pubitemid 39592859)
11. M. Caron, M.P. Emery, P. Marquis Recent trends in the inclusion of patient-reported outcomes (PRO) data in approved drugs labelling by the FDA and EMA PRO Newsl 40 2008 8 10
12. M. Goozner Patient reported outcomes poised for takeoff after final FDA guidance The Pink Sheet 72 004 2010 Art No. 00720040011
13. Marquis P, Caron M, Emery M, et al. The role of health-related quality of life data in the drug approval process in the USA and Europe: a review of guidance documents and authorizations of medicinal products from 2006 to 2010. Poster presented at International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD, May 2011.
14. K. Gondek, P. Sagnier, K. Gilchrist Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels J Clin Oncol 25 2007 5087 5093 (Pubitemid 350232288)
15. M. Mordin, S. Lewis, A. Gnanasakthy Patient-reported outcomes in product development guidance Value Health 13 2010 A17 (Abstract PMC21)
16. J.R. Johnson, G. Williams, R. Pazdur Endpoints and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 2003 1404 1411 (Pubitemid 46606423)
17. M. Mordin, M. Clark, C. Siersma Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Value Health 12 2009 A29 (Abstract PMC55)
18. K.M. Kamal, S.P. Desselle, P. Rane Content analysis of FDA warning letters to manufacturers of pharmaceuticals and therapeutic biologicals for promotional violations Drug Inf J 43 2009 385 393